

1 **Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test**  
2 **(sVNT)**

3  
4 **Benjamin Meyer<sup>#,1</sup>, Johan Reimerink<sup>#,2</sup>, Giulia Torriani<sup>3</sup>, Fion Brouwer<sup>2</sup>, Gert-Jan Godeke<sup>2</sup>,**  
5 **Sabine Yerly<sup>4</sup>, Marieke Hoogerwerf<sup>2</sup>, Nicolas Vuilleumier<sup>5,6</sup>, Laurent Kaiser<sup>4,7,8</sup>, Isabella**  
6 **Eckerle<sup>#,\*,3,7,8</sup>, Chantal Reusken<sup>#,\*,2</sup>**

7  
8 #contributed equally  
9 \*corresponding authors

10  
11 **Affiliations:**

12 *<sup>1</sup>Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva,*  
13 *Geneva, Switzerland*

14 *<sup>2</sup>Centre for Infectious Disease Control, WHO COVID-19 reference laboratory, RIVM, Bilthoven,*  
15 *the Netherlands*

16 *<sup>3</sup>Department of Microbiology and Molecular Medicine, University of Geneva, Geneva,*  
17 *Switzerland*

18 *<sup>4</sup>Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland*

19 *<sup>5</sup>Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and*  
20 *Geneva University, Geneva, Switzerland*

21 *<sup>6</sup>Division of Laboratory Medicine, Department of Medicine, Faculty of Medicine, Geneva,*  
22 *Switzerland*

23 *<sup>7</sup>Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland*

24 *<sup>8</sup>Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,*  
25 *Switzerland*

26  
27 **Address for correspondence:**

28 Chantal Reusken: [chantal.reusken@rivm.nl](mailto:chantal.reusken@rivm.nl)

29 Isabella Eckerle: [Isabella.Eckerle@hcuge.ch](mailto:Isabella.Eckerle@hcuge.ch)

30  
31 **Keywords:** SARS-CoV-2, neutralizing antibodies, surrogate virus neutralisation assay,  
32 pseudovirus neutralisation assay, cell-based virus neutralisation assay

33  
34 **Word count:**3519

35 **Abstract**

36 To understand SARS-CoV-2 immunity after natural infection or vaccination, functional assays  
37 such as virus neutralizing assays are needed. So far, assays to determine SARS-CoV-2  
38 neutralizing antibodies rely on cell-culture based infection assays either using wild type SARS-  
39 CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety  
40 facilities and are difficult to standardize.

41 Recently, a new surrogate virus neutralisation assay (sVNT) was described that uses the principle  
42 of an ELISA to measure the neutralization capacity of anti-SARS-CoV-2 antibodies directed  
43 against the receptor binding domain.

44 Here, we performed an independent evaluation of the robustness, specificity and sensitivity on an  
45 extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples  
46 collected before 2020 and compared it to cell-based neutralization assays.

47 We found a high specificity of 99.2 (95%CI: 96.9-99.9) and overall sensitivity of 80.3 (95%CI:  
48 74.9-84.8) for the sVNT. Clinical sensitivity increased between early (<14 days post symptom  
49 onset or post diagnosis, dpos/dpd) and late sera (>14 dpos/dpd) from 75.0 (64.7-83.2) to 83.1  
50 (76.5-88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon  
51 comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3  
52 (56.4-86.9) and 98.2 (89.4-99.9) for titres  $\geq 10$  to <40 and  $\geq 40$  to <160, respectively. Only samples  
53 with a titre  $\geq 160$  were always positive in the sVNT.

54 In conclusion, the sVNT can be used as an additional assay to determine the immune status of  
55 COVID-19 infected or vaccinated individuals but its value needs to be assessed for the specific  
56 context of use.

## 57 **Introduction**

58 In 2020, the world is facing an unprecedented global health crisis through the emergence of the  
59 novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative  
60 agent of the disease COVID-19. The pandemic spread of this virus immediately raised a demand  
61 for serological assays to support clinical and public health management, e.g. to determine a  
62 recent or past infection, to assess the level of (sub) population exposure and, to investigate  
63 different types of immune response and levels of potential immunity against re-infection.

64 Seven months into the outbreak a plethora of serological assays is available<sup>1</sup> that allows the  
65 routine detection of several classes of antibodies, i.e. IgM, IgG and IgA<sup>2-5</sup>. However, to  
66 understand immunity after natural infection or vaccination, a functional analysis of the elicited  
67 antibody responses, such as avidity for the most immunogenic viral antigens and virus  
68 neutralizing activity, is of utmost importance<sup>6</sup>.

69 So far, assays to determine SARS-CoV-2 neutralizing capability of antibodies rely on handling of  
70 wild type or pseudotyped viruses and use cell-culture based infection as a read-out. This requires  
71 a biosafety level (BSL) 3 laboratory for wild type SARS-CoV-2, or a BSL-2 laboratory for  
72 pseudotyped viruses such as vesicular stomatitis virus (VSV) or lentivirus-based systems. These  
73 in-house assays are difficult to standardize across laboratories, especially in the absence of an  
74 international standard, as assay characteristics vary depending on culture conditions, virus strains  
75 and cell lines used. Furthermore, these assays are labour-intensive, require highly skilled  
76 personnel, have a low throughput and results are only available after several days.

77 Recently, a first commercial assay has become available<sup>7</sup> that indirectly and semi- quantitatively  
78 measures the neutralizing functionality of SARS-CoV-2 antibodies while overcoming the above  
79 limitations. During natural infection, SARS-CoV-2 binds to its cellular receptor, the angiotensin-  
80 converting enzyme 2 (ACE2), via the receptor binding domain (RBD) of the viral spike (S)  
81 glycoprotein, which is an essential step to establish infection of the cell<sup>8,9</sup>. The majority, but not  
82 all, of the neutralising antibodies are directed against the RBD leading to an inhibition of this  
83 interaction<sup>6</sup>. The assay detects SARS-CoV-2 antibodies that competitively inhibit the interaction  
84 between recombinant RBD-HRP fusion protein and recombinant ACE2 that is coated on 96-well  
85 plates. The assay is independent of the use of replicating or pseudotyped virus and cell cultures  
86 and uses the same format/set-up as Enzyme-Linked Immunosorbent Assays (ELISA), allowing  
87 for high-throughput, automation and fast turnaround times.

88 Here, we present an independent, two-centre evaluation of the robustness, specificity and  
89 sensitivity of a commercially available version of this novel functional immune-assay based on an  
90 extensive panel of sera from a) a heterogeneous cohort of PCR-confirmed COVID-19 patients, b)

91 pre-outbreak syndromic patients with respiratory complaints including confirmed recent infections  
92 with the four common human coronaviruses (HCoV) and c) pre-outbreak population sera. The  
93 assay performance was evaluated against the conventional cell culture-based wildtype SARS-  
94 CoV-2 (Gold Standard method) and VSV-based pseudo-type neutralization assays to assess its  
95 value to measure levels of functional antibodies directed against SARS-CoV-2.

96

## 97 **Material and Methods**

### 98 **Sample collection**

99 RIVM: sera from common CoV cases and non-CoV respiratory cases were partially obtained from  
100 a previous study approved by the ethics committee of the National Institute of Public Health and  
101 the Environment (METC Noord-Holland, <http://www.trialregister.nl>; NTR3386 and 4818<sup>10</sup> and  
102 partially from anonymized leftover serum from routine diagnostics for respiratory pathogens or  
103 SARS-CoV-2 for which ethical approval was waived by the ethics committees of Brabant and  
104 Utrecht (NW2020-31 and NL13529.041.06; 06/282). The current study was performed in  
105 accordance with the guidelines for sharing of patient data of observational scientific research in  
106 emergency situations as issued by the Commission on Codes of Conduct of the Federation of  
107 Dutch Medical Scientific Societies (<https://www.federa.org/federa-english>).

108 University of Geneva/HUG: Anonymized leftovers of serum and plasma samples were used for  
109 this analysis. Ethical approval for all samples used in this study was waived by the local ethics  
110 committee of the HUG that approves usage of leftover of patient samples collected for diagnostic  
111 purposes in accordance with our institutional and national regulations.

112 The study included blood samples from 269 real-time (RT)-PCR confirmed COVID-19 cases  
113 (sensitivity panel) and 259 unmatched samples collected before 2020 (specificity panel). We used  
114 days post onset of symptoms (dpos) in cases where the onset was known or days post PCR  
115 diagnosis (dpd) if the onset was unknown. Samples were stored at -20°C and thawed immediately  
116 before the assay was performed. The specificity panel included sera collected before 2020 from  
117 healthy blood donors (n=100), patients with other respiratory diseases including (i) a two months  
118 earlier PCR-confirmed common HCoV infection, HCoV-229E (n=12), HCoV-NL63 (n=10), HCoV-  
119 HKU1 (n=6) or HCoV-OC43 (n=10)<sup>10</sup>, (ii) patients with a recent PCR-confirmed non-CoV  
120 respiratory infection (n=14) i.e. Influenza A virus (n=3), human metapneumovirus (HMPV) (n=4),  
121 respiratory syncytial virus (RSV) B (n=1), RSV A + HMPV (n=1), hemophilus influenza (n=1),  
122 mycoplasma pneumonia (n=1) and rhinovirus (n=3). Further it included patients with respiratory  
123 complaints that tested negative for a suspected *Bordetella pertussis* infection (n=16), patients  
124 with an acute cytomegalovirus (n=10) or acute Epstein-Barr virus (n=10) infection as well as adult

125 (n=21) and child (n=50) patients who came for routine diagnostic purposes to the hospital (Table  
126 1). The sensitivity panel included sera from 269 PCR-confirmed COVID-19 patients. Of these  
127 sera, 92 were taken before and 177 after 14 dpos/dpd. Severity of disease ranged from  
128 asymptomatic (n=3) to mild (non-hospitalized, n=92), severe (hospitalized, n=87) and ICU-  
129 admitted/deceased (hospitalized, n=54). For 33 patients the severity of disease was unknown  
130 (Table 1).

131

### 132 **Surrogate SARS-CoV-2 Virus Neutralisation Test**

133 The surrogate virus neutralisation test (sVNT) (GenScript cPass™ SARS-CoV-2 Neutralization  
134 Antibody Detection Kit, Genscript, The Netherlands) was performed according to the  
135 manufacturer's instructions. Both laboratories used the same LOT number (20E012157). Briefly,  
136 serum samples as well as positive and negative assay controls were diluted 1:10 in sample  
137 dilution buffer and mixed with an equal volume of HRP-conjugated RBD. Controls were tested in  
138 duplicates and samples in singular. After a 30 minute incubation at 37 °C, 100 µl of this mixture  
139 was transferred to a 96-well plate coated with recombinant ACE2. After incubation at 37 °C for 15  
140 minutes, the supernatant was removed and the plate was washed 4x using the provided wash  
141 buffer. 100 µl TMB substrate was added and incubated for 15 minutes at room temperature before  
142 the reaction was stopped by addition of 50 µl stop solution. Plates were read at 450 nm  
143 immediately afterwards. Percentage reduction (%reduction) for each sample was calculated by  
144 using the following formula:

$$145 \quad \%reduction = \left(1 - \frac{OD450 (sample)}{Average\ OD450 (neg.\ ctrl.)}\right) \times 100$$

146

### 147 **VSV-based Pseudovirus Neutralisation Test (PNT<sub>50</sub>)**

148 The VSV-based pseudovirus neutralisation test, was done as described previously<sup>2</sup>. Briefly,  
149 African green monkey (VeroE6) cells were seeded in 96-well plates at  $2 \times 10^4$  cells per well and  
150 grown into confluent monolayer overnight. Sera from patients were inactivated at 56°C for 30  
151 minutes and diluted from 1:5 to 1:1280 in DMEM 2% fetal bovine serum (FBS). VSV-based  
152 SARS-CoV-2 pseudotypes (generated according to Berger, Rentsch, and Zimmer<sup>11</sup> and Torriani  
153 et al.<sup>12</sup> expressing a 19 amino acids C-terminal truncated spike protein<sup>13</sup> (NCBI Reference  
154 sequence: NC\_045512.2) were diluted in DMEM 2% FBS in order to have MOI=0.01 per well and  
155 added on top of serum dilutions (final serum dilutions obtained were from 1:10 to 1:2560). The  
156 virus-serum mix was incubated at 37°C, for 2h. Vero E6 were then infected with 100µl of virus-  
157 serum mixtures. After incubation at 37°C for 1.5h, cells were washed once with 1X PBS and

158 DMEM 10% FBS was added. After 16-20h of incubation at 37°C, 5% CO<sub>2</sub> cells were fixed with  
159 4% formaldehyde solution for 15min at 37°C and nuclei stained with 1µg/ml DAPI solution. GFP  
160 positive infected cells were counted with ImageXpress® Micro Widefield High Content Screening  
161 System (Molecular Devices) and data analyzed with MetaXpress 5.1.0.41 software.

162

### 163 **SARS-CoV-2 Virus Neutralisation Test**

164 SARS-CoV-2 virus neutralization tests were performed exactly as described<sup>14</sup>. Two-fold serial  
165 dilutions (starting at 1:10) of heat-inactivated sera (30 min, 56°C) were incubated in duplicate with  
166 100 TCID<sub>50</sub> of SARS-CoV-2 strain HCoV-19/Netherlands/ZuidHolland\_10004/2020 (EVAg cat.nr.  
167 014V-03968) at 35°C, 5% CO<sub>2</sub> for 1 h in 96-wells plates. Vero-E6 cells were added in a  
168 concentration of 2 x 10<sup>4</sup> cells per well and incubated for three days at 35°C in an incubator with  
169 5% CO<sub>2</sub>. The serum virus neutralization titre (VNT<sub>50</sub>) was defined as the reciprocal value of the  
170 sample dilution that showed a 50 % protection of virus growth. Samples with titres ≥ 10 were  
171 defined as SARS-CoV-2 seropositive.

172

### 173 **Wantai SARS-CoV-2 total antibody Assay**

174 The Wantai SARS-CoV-2 total antibody ELISA (Beijing Wantai Biological Pharmacy Enterprise,  
175 Beijing, China; catalogue number WS1096) was performed exactly according to the  
176 manufacturer's instructions<sup>3</sup>. This assay is a double-antigen sandwich ELISA using a recombinant  
177 RBD of SARS-CoV-2 as antigen. Optical density (OD) is measured at 450 nm and the antibody  
178 titre for each sample is calculated as the ratio of the reading of that sample to the reading of a  
179 calibrator (included in the kit): OD ratio.

180

### 181 **Statistical analysis**

182 Statistical analysis was performed with GraphPad Prism version 8.4.3 using Mann-Whitney or  
183 Kruskal-Wallis test with Dunn's multiple comparison test where appropriate. Linear regression  
184 was also performed using GraphPad Prism version 8.4.3. Calculation of sensitivity, specificity and  
185 95% confidence intervals (95%CI) was done using the VassarStats statistical toolbox  
186 (<http://www.vassarstats.net/>). Results with p values <0.05 were considered significant.

187

### 188 **Results**

189 In this study, we validated an ELISA-based surrogate SARS-CoV-2neutralisation assay (sVNT)  
190 using specificity and sensitivity panels as described above. Among the 259 samples in the  
191 specificity panel we identified two samples, one among the blood donors and one in the cohort

192 with a recent non-CoV respiratory infection (HMPV infected) that were positive using the  
193 manufacturer recommended cut-off of 20% reduction (%reduction: 97.2 and 21.6, respectively).  
194 Both samples were tested in the VNT<sub>50</sub> and did not show any SARS-CoV-2 neutralising activity.  
195 Considering an alternative cut-off of 30% reduction, as proposed in a recent publication by the  
196 manufacturer<sup>7</sup>, only the blood donor sample remained positive for blocking RBD binding to ACE2  
197 (Figure 1A). This indicates a specificity of 99.2 (95% CI: 96.9-99.9) and 99.6 (95% CI: 97.5-99.9),  
198 respectively (Table 2).

199  
200 Among the 269 sera of confirmed COVID-19 patients in the sensitivity panel, 216 sera tested  
201 positive in the sVNT resulting in an overall clinical sensitivity of 80.3 (95%CI: 74.9-84.8). In sera  
202 sampled before 14 dpos/dpd 69/92 samples blocked RBD-ACE2 interaction (clinical sensitivity  
203 75.0 (95%CI: 64.7-83.2) while 147/177 sera sampled at or after 14 dpos/dpd tested positive,  
204 resulting in an increased clinical sensitivity of 83.1 (95%CI: 76.5-88.1). In addition, median  
205 %reduction significantly increased between <14 and ≥14 dpos/dpd from 61.2% to 82.5% (Mann  
206 Whitney test, p=0.0019) (Figure 1B, 2A and Table 3). Furthermore, we analysed the relationship  
207 between the severity of COVID-19 disease and the clinical sensitivity of the sVNT as stronger  
208 immune responses were observed in severe vs mild cases<sup>14,15</sup>. We observed that the assay  
209 sensitivity increased with an increased disease severity, higher in hospitalised patients vs  
210 outpatients, regardless of the time of sampling. During the acute phase (<14dpos/dpd) of the  
211 infection, the clinical sensitivity in mild cases was 47.4% and increased to 70.7% and 100% in  
212 severe and ICU/deceased patients, respectively (Figure 1D and Table 3). A similar observation  
213 was made in samples collected ≥14 dpos/dpd, where sensitivity increased from 75.3% in mild  
214 cases to 91.3% and 88.2% in severe and ICU/deceased cases, respectively (Figure 1E and Table  
215 3). The median %reduction in the sVNT increased with disease severity, but this increase was  
216 only significant for mild vs severe and mild vs ICU/deceased cases both before and after  
217 14dpos/dpd (Kruskal-Wallis test) (Figure 1D and E). When considering the alternative cut-off of  
218 30% reduction to determine positivity in the sVNT, the clinical sensitivity of the assay decreased  
219 by 0-9%, but the overall picture remained unchanged (Table 3).

220  
221 As the novel assay is meant to be implemented as a surrogate assay for functional cell-based  
222 serological methods that measure SARS-CoV-2 neutralising capacity of antibodies, we compared  
223 the performance of the sVNT with the conventional VNT<sub>50</sub> and PNT<sub>50</sub> assays. The sVNT detected  
224 blocking of ACE2 binding activity in nine of 50 sera of confirmed COVID-19 patients that did not  
225 show SARS-CoV-2 neutralising activity in the cell-based assays (Table 3). Conversely, only 26/35

226 sera with a titre in the range of  $\geq 10$  to  $< 40$  as well as 56/57 sera with a titre in the range of  $\geq 40$  to  
227  $< 160$  in the cell-based neutralisation assays showed blocking activity in the sVNT. This results in  
228 an analytical sensitivity of 74.3 (95% CI: 56.4-86.9) and 98.2 (95% CI: 89.4-99.9) respectively  
229 when compared to conventional in-house neutralisation assays. Only sera (n=116) with a titre of  
230  $\geq 160$  in the PNT<sub>50</sub>/VNT<sub>50</sub> were always positive in the sVNT. The median %reduction in the four  
231 titre subgroups significantly increased with rising PNT<sub>50</sub>/VNT<sub>50</sub> titres from -2.6 ( $< 10$ ) to 36.0 ( $\geq 10$   
232 to  $< 40$ ), 75.6 ( $\geq 40$  to  $< 160$ ) and 92.5 ( $\geq 160$ ) (Kruskal-Wallis test) (Figure 1C). To further  
233 investigate the correlation of PNT<sub>50</sub>/VNT<sub>50</sub> titres with %reduction in the sVNT, a linear regression  
234 analysis was performed using all sera for which an endpoint titre was available (n=154). We found  
235 a moderate correlation between PNT<sub>50</sub> and sVNT %reduction ( $R^2 = 0.4937$ ,  $p > 0.0001$ ) (Figure 2B)  
236 and a slightly better correlation for VNT<sub>50</sub> titres ( $R^2 = 0.6548$ ,  $p > 0.0001$ ) (Figure 2C).

237  
238 We also compared overall clinical sensitivity and specificity of the assay between the two centres  
239 where the study was conducted (UNIGE and RIVM). Specificity was comparable with only minor  
240 differences between the two laboratories. In contrast, clinical sensitivity was markedly lower at  
241 UNIGE compared to samples analysed at RIVM (Table 4). However, samples from late time points  
242 dpos/dpd were underrepresented in the UNIGE sample set, giving a potential explanation for  
243 this discrepancy.

244  
245 Last, we investigated the interassay variance of the sVNT by testing a representative subset of  
246 samples at least five times at different days. Similar coefficients of variation (%CV) were found in  
247 both laboratories. We observed a very low %CV in samples with a mean %reduction  $> 90\%$ ,  
248 ranging from 0.22 to 4.63 %CV. However, the %CV increased to 3.55-13.73 in samples with a  
249 mean %reduction between 50-60% and to 10.39-20.39 in samples with a mean %reduction  
250 around 30%. Samples with a mean %reduction  $< 11\%$  gave a high %CV between 67.33-216.38  
251 (Table 5).

## 252 253 **Discussion**

254 The importance of serology in clinical and public health management of SARS-CoV-2 is reflected  
255 in the huge amount of immune-assays that are currently being developed or have been released  
256 on the diagnostic market<sup>1</sup>. However, a vast majority of these tests are simply measuring  
257 qualitatively or semi-quantitatively the presence of IgG, IgM and/or IgA but do not address the  
258 functionality of the antibody response elicited by a SARS-CoV-2 infection. Functional assays like  
259 virus neutralization tests are essential to address specific questions related to protective immunity

260 after vaccination or natural infection. However, these type of assays are operated based on in-  
261 house protocols and lack standardization across laboratories<sup>16–18</sup>. We performed an independent  
262 two-centre clinical evaluation of the GenScript cPass™ test, which is based on the principle of an  
263 inhibition ELISA, to assess its value for routine diagnostics and as surrogate functional assay to  
264 measure neutralizing capability in SARS-CoV-2 elicited antibody responses.

265  
266 We observed a high specificity of > 99% and an overall clinical sensitivity of 83% in samples taken  
267 ≥14 dpos. Within this group of confirmed COVID-19 patients, the clinical sensitivity was 75% in  
268 mild and 91% in hospitalized patients. Deeks and colleagues performed a Cochrane assessment  
269 of 54 studies using commercial immune-assays<sup>5</sup>. They concluded that in confirmed COVID-19  
270 patients sampled in the periods 15-21 dpos and 22-25 dpos, the sensitivities for IgG were  
271 respectively 88.2% (95% CI 83.5 to 91.8) and 80.3% (95%CI 72.4 to 86.4). While direct  
272 comparison of performances of different serology assays is complicated by differences in test set-  
273 up (e.g. testing for all isotypes vs for IgG only, the use of different antigens, measuring antigen  
274 binding vs prevention of RBD-ACE2 binding) and differences in patient cohorts used, our results  
275 seem to indicate that the sVNT might be a more powerful tool for cohort and population studies  
276 than for individual diagnosis of past SARS-CoV-2 infection as the observed sensitivities are in the  
277 lower end of the range of average test performances observed by Deeks.

278  
279 With respect to the sVNT as alternative for conventional virus culture-based assays measuring  
280 neutralizing activity, we observed that on the one hand the sVNT misses samples that have a low  
281 virus neutralization titre in these assays and on the other hand identifies samples as positive that  
282 were negative in a Gold Standard tests. A limitation of the sVNT is the restriction to RBD binding  
283 antibodies. It has been shown that SARS-CoV-2 infection does not only induce antibodies against  
284 the RBD or the S1 domain, but also against the S2 domain as well as against N<sup>19</sup>. While antibodies  
285 directed against the N protein are most likely non-neutralizing, antibodies directed against the N-  
286 terminal domain of S1 (outside of the RBD) have shown neutralizing potential<sup>20</sup>. In addition, for  
287 SARS-CoV-1 also antibodies directed at the S2 domain show neutralizing capabilities<sup>21</sup>. Although  
288 S2 domain-mediated neutralisation remains to be confirmed for SARS-CoV-2, assessing the  
289 neutralizing ability with the sVNT might indeed miss the presence of virus neutralizing capabilities  
290 directed outside of the RBD. Furthermore, all of the sera that were reactive in the sVNT but not in  
291 the VNT<sub>50</sub>/PNT<sub>50</sub> were reactive in the Wantai total Ig ELISA that targets RBD as well (data not  
292 shown). This indicates that the activity measured in the sVNT is likely due to antibodies directed  
293 against the RBD but without a virus neutralising capacity that leads to at least 50% reduction of

294 infected cells. Another explanation for such false positivity with respect to neutralizing capability  
295 might be the presence of anti-ACE2 autoantibodies as described for specific patient groups<sup>22,23</sup>.  
296 The observation of false positives and the observed lower sensitivity (74%) of the sVNT in  
297 comparison to conventional tests in samples with neutralizing antibody titres  $\geq 10$  and  $< 40$ , indicate  
298 that the sVNT cannot fully replace the Gold Standard immune-assays. Depending on the context  
299 of use, the lower sensitivity in the range of low virus neutralization titres might however be  
300 acceptable, e.g. for decision making on release of hospitalized patients with virus neutralization  
301 titres above a predetermined threshold from isolation units<sup>24,25</sup>. Nevertheless, as long as the  
302 correlates of protection for classical virus neutralization tests are not known, the use of the sVNT  
303 as functional assay to determine level of immunity is not warranted.

304  
305 Besides the aforementioned advantages of the possibility for increased standardization across  
306 laboratories, the possibility for automatization, the technical simplicity and the reduced biosafety  
307 risk, the sVNT is isotype- and species-independent. Species-independent serology tools are  
308 important for research into the epidemiology and ecology of SARS-CoV-2, i.e. for the identification  
309 of natural reservoirs and spill-over hosts as well as the monitoring and prevention of human risks  
310 from sustained virus circulation in farm animals such as minks (refs). In contrast to virus culture-  
311 based assays, the sVNT is at most a semi-quantitative assay making it less valuable as functional  
312 assay in immunity studies.

313  
314 In conclusion, the sVNT can be used as an additional assay to determine the immune status of  
315 COVID-19 infected or vaccinated individuals and cohort studies to confirm results of more routine  
316 immuno-assays like IgG, IgM and/or IgA ELISAs and CLIAs. The value of the sVNT as functional  
317 assay in patient management, biosafety management, vaccine and immunity studies needs to be  
318 assessed for the specific context of use.

319  
320 **Figure Legends:**

321 **Figure 1:** %reduction (inhibition of RBD-ACE2 binding) of samples of the specificity panel).  
322 %reduction of PCR-confirmed COVID-19 patient samples stratified **(A)** by days post onset of  
323 symptoms (dpos) or days post diagnosis (dpd) **(B)**, by results of PNT<sub>50</sub>/VNT<sub>50</sub> titre **(C)** and by  
324 disease severity **(D and E)**. Dashed line indicates 20% or 30% cut-off (CO).

325

326 **Figure 2:** %reduction (inhibition of RBD-ACE2 binding) of COVID-19 patient samples by dpos/dpd  
327 and disease severity (**A**). Linear correlation of PNT<sub>50</sub> (**B**) and VNT<sub>50</sub> (**C**) endpoint titres with  
328 %reduction of RBD-ACE2 binding. Dashed line indicates 20% or 30% cut-off (CO).

329  
330 **Acknowledgements:** We would like to thank Romain Burquier (HUG, Geneva) for technical  
331 assistance and Barbara Lemaitre (HUG, Geneva) and Shefije Fejza (HUG, Geneva) for help with  
332 sample preparation. We are grateful to Jean-Luc Murk (Elizabeth-Tweesteden Ziekenhuis,  
333 Tilburg, the Netherlands), Afke Brandenburg (Izore, Leeuwarden, the Netherlands) and Bas  
334 Wintermans (Admiraal de Ruyter Ziekenhuis, Goes, the Netherlands), Josine van Beek and  
335 Kristin Kremer (RIVM) for provision of panel samples and Mariette Edema (RIVM) for support. This  
336 study was supported by a grant from the Private Foundation of the Geneva University Hospital.

337

### 338 **Bibliography**


- 339 1. Foundation for Innovative New Diagnostics. FIND evaluation update: SARS-CoV-2  
340 immunoassays. *FIND evaluation update: SARS-CoV-2 immunoassays*  
341 <https://www.finddx.org/covid-19/sarscov2-eval-immuno/> (2020).
- 342 2. Meyer, B. *et al.* Validation of a commercially available SARS-CoV-2 serological  
343 immunoassay. *Clinical Microbiology and Infection* S1198743X20303682 (2020)  
344 doi:10.1016/j.cmi.2020.06.024.
- 345 3. Lassaunière, R. *et al.* Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv*  
346 2020.04.09.20056325 (2020) doi:10.1101/2020.04.09.20056325.
- 347 4. GeurtsvanKessel, C. H. *et al.* An evaluation of COVID-19 serological assays informs future  
348 diagnostics and exposure assessment. *Nat Commun* **11**, 3436 (2020).
- 349 5. Deeks, J. J. *et al.* Antibody tests for identification of current and past infection with SARS-  
350 CoV-2. *Cochrane Database of Systematic Reviews* (2020)  
351 doi:10.1002/14651858.CD013652.
- 352 6. Barnes, C. O. *et al.* Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal  
353 Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842.e16 (2020).

- 354 7. Tan, C. W. *et al.* A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on  
355 antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction.  
356 <https://www.researchsquare.com/article/rs-24574/v1> (2020) doi:10.21203/rs.3.rs-24574/v1.
- 357 8. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.  
358 *Science* eabb2507 (2020) doi:10.1126/science.abb2507.
- 359 9. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is  
360 Blocked by a Clinically Proven Protease Inhibitor. *Cell* S0092867420302294 (2020)  
361 doi:10.1016/j.cell.2020.02.052.
- 362 10. van Beek, J. *et al.* Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination  
363 in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza  
364 Virus Infections. *The Journal of Infectious Diseases* **216**, 415–424 (2017).
- 365 11. Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay for  
366 the rapid and sensitive determination of multi-species type I interferon. *PLoS ONE* **6**,  
367 e25858 (2011).
- 368 12. Torriani, G. *et al.* Identification of Clotrimazole Derivatives as Specific Inhibitors of  
369 Arenavirus Fusion. *J. Virol.* **93**, (2019).
- 370 13. Fukushi, S. *et al.* Vesicular stomatitis virus pseudotyped with severe acute respiratory  
371 syndrome coronavirus spike protein. *J. Gen. Virol.* **86**, 2269–2274 (2005).
- 372 14. Rijkers, G. *et al.* Differences in Antibody Kinetics and Functionality Between Severe and  
373 Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. *The Journal of*  
374 *Infectious Diseases* jiaa463 (2020) doi:10.1093/infdis/jiaa463.
- 375 15. Cervia, C. *et al.* Systemic and mucosal antibody secretion specific to SARS-CoV-2 during  
376 mild versus severe COVID-19. <http://biorxiv.org/lookup/doi/10.1101/2020.05.21.108308>  
377 (2020) doi:10.1101/2020.05.21.108308.
- 378 16. Muruato, A. E. *et al.* A high-throughput neutralizing antibody assay for COVID-19 diagnosis  
379 and vaccine evaluation. *Nat Commun* **11**, 4059 (2020).

- 380 17. Zettl, F. *et al.* Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using  
381 Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. *Vaccines* **8**, 386 (2020).
- 382 18. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*  
383 **581**, 465–469 (2020).
- 384 19. Grzelak, L. *et al.* A comparison of four serological assays for detecting anti-SARS-CoV-2  
385 antibodies in human serum samples from different populations. *Sci. Transl. Med.* **12**,  
386 eabc3103 (2020).
- 387 20. Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike  
388 protein of SARS-CoV-2. *Science* **369**, 650–655 (2020).
- 389 21. Duan, J. *et al.* A human SARS-CoV neutralizing antibody against epitope on S2 protein.  
390 *Biochem. Biophys. Res. Commun.* **333**, 186–193 (2005).
- 391 22. Takahashi, Y., Haga, S., Ishizaka, Y. & Mimori, A. Autoantibodies to angiotensin-converting  
392 enzyme 2 in patients with connective tissue diseases. *Arthritis Res Ther* **12**, R85 (2010).
- 393 23. McMillan, P., MB, BS, MRCP & Uhal, B. D., PhD. COVID-19—A theory of autoimmunity to  
394 ACE-2. *MOJ Immunology* **7**, 17–19 (2020).
- 395 24. Singanayagam, A. *et al.* Duration of infectiousness and correlation with RT-PCR cycle  
396 threshold values in cases of COVID-19, England, January to May 2020. *Eurosurveillance*  
397 **25**, (2020).
- 398 25. van Kampen, J. J. A. *et al.* *Shedding of infectious virus in hospitalized patients with*  
399 *coronavirus disease-2019 (COVID-19): duration and key determinants.*  
400 <http://medrxiv.org/lookup/doi/10.1101/2020.06.08.20125310> (2020)  
401 doi:10.1101/2020.06.08.20125310.


402

**Figure 1**




## Figure 2


**A**



**B**



**C**



**Table 1: Demographics**

Cohort	N	Collection year	Age range	Sex		
				Female	Male	Unknown
Pre-pandemic samples	259					
Adult patients	21	2018	25-71	15	6	0
Child patients	50	2018	1-11	24	26	0
CMV	10	2016	Unknown	0	0	10
EBV	10	2016	Unknown	0	0	10
Suspected Pertussis	16	2019	<18	0	0	16
Other Resp. Diseases	52	2011-2015	>60	0	0	52
Blood Donors	100	2016	18-79	0	0	100
PCR-confirmed COVID-19 patients	269	2020	24-91	66	136	67
<14 dpos/dpd	92		24-88	22	59	11
≥14 dpos/dpd	177		24-91	44	77	56
Severity						
Asymptomatic	3		57-71	0	3	0
Mild	92		24-91	29	31	32
Severe	87		42-88	24	49	14
ICU/Deceased	54		56-87	8	29	17
unknown	33		37-83	5	24	4

**Table 2: Specificity of sVNT**

Category	Total (n)	20% Cut-off			30% Cut-off		
		Positive (%)	Negative (%)	Specificity (95% CI)	Positive (%)	Negative (%)	Specificity (95% CI)
Pre-pandemic adult patients	21	0 (0)	21 (100)	100 (80.8-100)	0 (0)	21 (100)	100 (80.8-100)
Pre-pandemic child patients	50	0 (0)	50 (100)	100 (91.1-100)	0 (0)	50 (100)	100 (91.1-100)
CMV	10	0 (0)	10 (100)	100 (65.5-100)	0 (0)	10 (100)	100 (65.5-100)
EBV	10	0 (0)	10 (100)	100 (65.5-100)	0 (0)	10 (100)	100 (65.5-100)
Suspected Pertussis	16	0 (0)	16 (100)	100 (75.9-100)	0 (0)	16 (100)	100 (75.9-100)
Other Resp. Diseases	52	1 (1.9)	51 (98.1)	98.1 (88.4-99.9)	0 (0)	52 (100)	100 (91.4-100)
Blood Donors	100	1 (1.0)	99 (99.0)	99.0 (93.8-99.9)	1 (1.0)	99 (99.0)	99.0 (93.8-99.9)
Total	259	2 (0.8)	257 (99.2)	99.2 (96.9-99.9)	1 (0.4)	257 (99.6)	99.6 (97.5-99.9)

CMV, cytomegalovirus; EBV, Epstein-Barr virus; ILI, influenza like illness; 95% CI, 95% confidence interval

**Table 3: Sensitivity of sVNT**

Category	Total	20% Cut-off			30% Cut-off		
		Positive (%)	Negative (%)	Sensitivity % (95% CI)	Positive (%)	Negative (%)	Sensitivity % (95% CI)
All	269	216 (80.3)	53 (19.7)	80.3 (74.9-84.8)	207 (77.0)	62 (23.0)	77.0 (71.4-81.8)
dpos/dpd							
<14 days	92	69 (75.0)	23 (25.0)	75.0 (64.7-83.2)	68 (73.9)	24 (26.1)	73.9 (63.5-82.3)
≥14 days	177	147 (83.1)	30 (16.9)	83.1 (76.5-88.1)	139 (78.5)	38 (21.5)	78.5 (71.6-84.2)
P-NT50/VNT50							
<10	50	9 (18.0)	41 (82.0)	18.0 (9.0-31.9)	6 (12.0)	44 (88.0)	12.0 (5.0-25.0)
≥10 to <40	35	26 (74.3)	9 (25.7)	74.3 (56.4-86.9)	24 (68.6)	11 (31.4)	68.6 (50.6-82.6)
≥40 to <160	57	56 (98.2)	1 (1.8)	98.2 (89.4-99.9)	55 (96.3)	2 (3.7)	96.3 (86.2-99.4)
≥160	116	116 (100)	0 (0)	100 (96.0-100)	115 (99.1)	1 (0.9)	99.1 (94.6-100)
ND	11	9 (81.8)	2 (18.2)	81.8 (47.8-96.8)	7 (63.6)	4 (36.4)	63.6 (31.6-87.6)
Severity <14 dpos/dpd							
Mild	19	9 (47.4)	10 (52.6)	47.4 (25.2-70.5)	9 (47.4)	10 (52.6)	47.4 (25.2-70.5)
Severe	41	29 (70.7)	12 (29.3)	70.7 (54.3-83.4)	29 (70.7)	12 (29.3)	70.7 (54.3-83.4)
Deceased	20	20 (100)	0 (0)	100 (80.0-100)	20 (100)	0 (0)	100 (80.0-100)
unknown	12	11 (91.7)	1 (8.3)	91.7 (59.8-99.6)	10 (83.3)	2 (16.7)	83.3 (50.9-97.1)
Severity ≥14 dpos/dpd							
Asymptomatic	3	2 (66.7)	1 (33.3)	66.7 (12.5-98.2)	2 (66.7)	1 (33.3)	66.7 (12.5-98.2)
Mild	73	55 (75.3)	18 (24.7)	75.3 (63.6-84.4)	50 (68.5)	23 (31.5)	68.5 (56.4-78.6)
Severe	46	42 (91.3)	4 (8.7)	91.3 (78.3-97.2)	41 (89.1)	5 (10.9)	89.1 (75.6-95.9)
ICU/Deceased	34	30 (88.2)	4 (11.8)	88.2 (71.6-96.2)	30 (88.2)	4 (11.8)	88.2 (71.6-96.2)
unknown	21	18 (85.7)	3 (14.3)	85.7 (62.6-96.2)	16 (76.2)	5 (23.8)	76.2 (52.5-90.9)

DPOS, days post onset of symptoms; DPD days post diagnosis; P-NT50 pseudovirus neutralization test 50% inhibition titer; VNT50 virus neutralization test 50% inhibition titer; ND, not determined; 95% CI, 95% confidence interval

**Table 4: Comparison of sVNT between sites**

	UNIGE		RIVM	
	20% Cut-off	30% Cut-off	20% Cut-off	30% Cut-off
Overall Specificity (95% CI)	100 (93.6-100)	100 (93.6-100)	98.9 (95.8-99.8)	99.5 (96.6-99.9)
Overall Sensitivity (95% CI)	70.9 (56.9-81.9)	63.6 (49.5-75.8)	82.7 (76.8-87.4)	80.4 (74.3-85.3)

95% CI, 95% confidence interval

**Table 5: Interassay variance of sVNT**

UNIGE					RIVM				
Sample	No. of repeats	Mean % reduction	SD	% CV	Sample	No. of repeats	Mean % reduction	SD	% CV
					001	5	-4.35	3.30	75.82
					002	5	4.10	8.87	216.39
49_neg_2018	5	7.70	5.18	67.33	003	5	10.28	9.09	88.45
30193717	5	30.21	3.14	10.39	004	5	31.66	6.46	20.39
					005	5	32.75	5.00	15.25
30189617	5	57.29	2.03	3.55	006	5	53.76	7.38	13.73
					007	5	54.89	2.47	4.50
					008	5	92.38	4.28	4.63
30175147	5	96.30	0.21	0.22	009	5	93.71	2.63	2.80

SD, standard deviation; CV, coefficient of variation